Immune Design Corp. (IMDZ) Shares Up 9.8% After Insider Buying Activity
Immune Design Corp. (NASDAQ:IMDZ) traded up 9.8% during trading on Thursday following insider buying activity. The company traded as high as $8.26 and last traded at $8.26, with a volume of 95,725 shares trading hands. The stock had previously closed at $7.52.
Specifically, Director Lewis W. Coleman purchased 40,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 20th. The stock was bought at an average price of $6.25 per share, for a total transaction of $250,000.00. Following the completion of the purchase, the director now directly owns 50,000 shares of the company’s stock, valued at $312,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 42.90% of the stock is currently owned by corporate insiders.
A number of research analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of Immune Design Corp. from a “hold” rating to a “sell” rating in a research note on Tuesday, July 12th. Leerink Swann reiterated a “buy” rating on shares of Immune Design Corp. in a research note on Friday, June 10th. Finally, Jefferies Group reiterated a “buy” rating and issued a $17.00 price target (down previously from $20.00) on shares of Immune Design Corp. in a research note on Wednesday, August 10th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $14.50.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/immune-design-corp-imdz-shares-up-9-8-after-insider-buying-activity.html
The company’s market cap is $165.44 million. The firm has a 50 day moving average price of $7.07 and a 200-day moving average price of $10.24.
Immune Design Corp. (NASDAQ:IMDZ) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($0.71) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.68) by $0.03. Immune Design Corp. had a negative net margin of 525.30% and a negative return on equity of 44.57%. Equities analysts expect that Immune Design Corp. will post ($2.70) EPS for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Highbridge Capital Management LLC acquired a new stake in Immune Design Corp. during the second quarter worth about $215,000. Panagora Asset Management Inc. increased its stake in Immune Design Corp. by 8.0% in the second quarter. Panagora Asset Management Inc. now owns 96,644 shares of the company’s stock worth $789,000 after buying an additional 7,190 shares during the period. State Street Corp increased its stake in Immune Design Corp. by 23.5% in the second quarter. State Street Corp now owns 207,670 shares of the company’s stock worth $1,694,000 after buying an additional 39,551 shares during the period. Spark Investment Management LLC increased its stake in Immune Design Corp. by 110.0% in the second quarter. Spark Investment Management LLC now owns 77,500 shares of the company’s stock worth $632,000 after buying an additional 40,600 shares during the period. Finally, Pictet Asset Management Ltd. increased its stake in Immune Design Corp. by 768.9% in the second quarter. Pictet Asset Management Ltd. now owns 748,145 shares of the company’s stock worth $9,389,000 after buying an additional 662,045 shares during the period. 48.03% of the stock is owned by institutional investors.
Immune Design Corp. Company Profile
Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo.
Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with MarketBeat.com's FREE daily email newsletter.